GILEAD SCIENCES, INC. — Director's Dealing 2016

May 31, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2016-05-24

Reporting Person: YOUNG KEVIN (Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1126	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-qualified Stock Option (Right to Buy)	$40.56	2023-02-01	Common Stock (27118)		Direct
Non-qualified Stock Option (Right to Buy)	$80.65	2024-02-01	Common Stock (4641)		Direct
Non-qualified Stock Option (Right to Buy)	$98.32	2025-02-10	Common Stock (6820)		Direct
Non-qualified Stock Option (Right to Buy)	$87.80	2026-02-10	Common Stock (7715)		Direct
Restricted Stock Unit	$	2026-02-10	Common Stock (8060)		Direct

Footnotes

F1: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.